HCC

Hepatocellular Carcinoma (HCC) is the most common type of primary liver cancer and represents a significant health challenge worldwide. It usually develops in the setting of chronic liver disease and cirrhosis, commonly caused by hepatitis B or C virus infections, alcohol-related liver damage, or nonalcoholic fatty liver disease. Early detection of HCC greatly improves treatment outcomes, but symptoms often appear late, including abdominal pain, unintended weight loss, jaundice, and swelling in the abdomen. Diagnosis commonly involves imaging techniques such as ultrasound, CT scans, and MRI, along with blood tests including alpha-fetoprotein levels. Treatment options vary depending on the stage of cancer and liver function and can range from surgical resection, liver transplantation, local ablation therapies, to systemic treatments like targeted therapy and immunotherapy. Preventive measures focusing on vaccination against hepatitis B, controlling hepatitis C infection, managing lifestyle factors, and regular screening for high-risk individuals can effectively reduce the incidence and mortality rates associated with HCC. Understanding HCC’s risk factors, strategies for early diagnosis, and available treatments empowers patients and healthcare providers to take proactive steps toward managing this condition. Awareness and education are key in improving prognosis and quality of life for those affected by this complex liver disease.